Last reviewed · How we verify
DP303c
DP303c is a small molecule that targets the SGLT2 receptor.
DP303c is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | DP303c |
|---|---|
| Also known as | DP303c treatment, DP303c |
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
DP303c works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors (PHASE1, PHASE2)
- A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (PHASE1, PHASE2)
- DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer (PHASE3)
- DP303c in Patients With HER2-positive Advanced Breast Cancer (PHASE3)
- A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors (PHASE1)
- DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer (PHASE2)
- Study of DP303c Injection in Patients With Advanced Ovarian Cancer (PHASE2)
- Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DP303c CI brief — competitive landscape report
- DP303c updates RSS · CI watch RSS
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI